Overview

Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients

Status:
Completed
Trial end date:
2019-04-18
Target enrollment:
Participant gender:
Summary
The study is designed to approve non-inferior efficacy and safety of Insulin Lispro Biphasic 25 ("Geropharm") compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients.
Phase:
Phase 3
Details
Lead Sponsor:
Geropharm
Treatments:
Biphasic Insulins
Insulin
Insulin Lispro
Insulin, Globin Zinc
Insulin, Isophane